Acute Liver Failure Treatment

Etiology-Specific Treatments

The American Association for the Study of Liver Diseases recommends that viral hepatitis A and B-related ALF must be treated with supportive care as no virus-specific treatment has been proven effective 1, 2
For patients with hepatitis B who require chemotherapy or immunosuppression, the American Association for the Study of Liver Diseases suggests nucleoside analogs should be given prior to and continued for 6 months after completion of treatment to prevent reactivation 2, 3
Patients with known or suspected herpes virus or varicella zoster as the cause of ALF must be immediately placed on the liver transplant list and treated with acyclovir, as recommended by the American Association for the Study of Liver Diseases 2, 4
Wilson disease-related ALF is considered uniformly fatal without transplantation, according to the American Association for the Study of Liver Diseases 2, 5
The American Association for the Study of Liver Diseases recommends treatment to acutely lower serum copper and limit hemolysis should include albumin dialysis, continuous hemofiltration, plasmapheresis, or plasma exchange in Wilson disease-related ALF 5, 3
Penicillamine is not recommended in ALF due to risk of hypersensitivity, as stated by the American Association for the Study of Liver Diseases 5
Liver biopsy should be considered to establish a diagnosis of autoimmune hepatitis, according to the American Association for the Study of Liver Diseases 5
The American Association for the Study of Liver Diseases recommends treating autoimmune hepatitis with corticosteroids (prednisone, 40-60 mg/day) 5
Patients with autoimmune hepatitis should be placed on the transplant list even while corticosteroids are being administered, as suggested by the American Association for the Study of Liver Diseases 5
Consultation with obstetrical services and expeditious delivery are recommended for acute fatty liver of pregnancy/HELLP syndrome, according to the American Association for the Study of Liver Diseases 5, 6
Recovery is typically rapid after delivery, with supportive care as the only other treatment required for acute fatty liver of pregnancy/HELLP syndrome, as stated by the American Association for the Study of Liver Diseases 6
The American Association for the Study of Liver Diseases recommends discontinuing all but essential medications in drug-induced hepatotoxicity 4
Obtaining a detailed medication history including prescription drugs, non-prescription medications, herbs, and dietary supplements is crucial in drug-induced hepatotoxicity, according to the American Association for the Study of Liver Diseases 4
Consider administration of penicillin G and silymarin in mushroom poisoning, as recommended by the American Association for the Study of Liver Diseases 4
Patients with mushroom poisoning should be listed for transplantation, as this procedure is often the only lifesaving option, according to the American Association for the Study of Liver Diseases 4

Supportive Care Management

Hemodynamic Support

Careful attention must be paid to fluid resuscitation and maintenance of adequate intravascular volume, as recommended by the American Association for the Study of Liver Diseases 7, 8
Pulmonary artery catheterization should be considered in hemodynamically unstable patients, according to the American Association for the Study of Liver Diseases 8, 9
If fluid replacement fails to maintain mean arterial pressure of 50-60 mm Hg, use systemic vasopressor support with agents such as epinephrine, norepinephrine, or dopamine (but not vasopressin), as suggested by the American Association for the Study of Liver Diseases 8, 9

Metabolic Management

Manage hypoglycemia with continuous glucose infusions, as recommended by the American Association for the Study of Liver Diseases 9
Monitor and supplement phosphate, magnesium, and potassium levels as needed, according to the American Association for the Study of Liver Diseases 9
Initiate enteral feedings early with moderate protein intake (approximately 60 grams per day), as suggested by the American Association for the Study of Liver Diseases 9
If enteral feedings are contraindicated, parenteral nutrition is an option despite risks of fungal infection, according to the American Association for the Study of Liver Diseases 9

Renal Support

If dialysis support is needed for acute renal failure, use continuous modes rather than intermittent modes, as recommended by the American Association for the Study of Liver Diseases 9

Liver Transplantation

Urgent hepatic transplantation is indicated in ALF where prognostic indicators suggest a high likelihood of death, according to the American Association for the Study of Liver Diseases 9
Post-transplant survival rates for ALF have been reported to be as high as 80% to 90%, as stated by the American Association for the Study of Liver Diseases 8
Poor prognostic indicators include idiosyncratic drug injury, non-hepatitis A viral infections, autoimmune hepatitis, mushroom poisoning, Wilson disease, Budd-Chiari syndrome, and indeterminate cause, according to the American Association for the Study of Liver Diseases 7

Liver Support Systems

Various liver support systems have been tested with no certain evidence of efficacy, as stated by the American Association for the Study of Liver Diseases 9
Sorbent systems may show transient improvement of hepatic encephalopathy but no improvement in hepatic function or long-term benefit, according to the American Association for the Study of Liver Diseases 9
Recent studies have shown improved short-term survival for some patients with ALF treated with porcine hepatocyte-based bioartificial liver, but further research is needed, as recommended by the American Association for the Study of Liver Diseases 9

Acute Liver Failure Management

Diagnostic Considerations

Indeterminate etiology of acute liver failure may be investigated with transjugular liver biopsy to identify specific etiology that might influence treatment 10
Systemic corticosteroids are ineffective for general ALF treatment, except in autoimmune hepatitis 10
Changes in aminotransferase levels correlate poorly with prognosis in acute liver failure patients 10
Malignant infiltration of the liver can mimic ALF, and should be considered in patients with previous cancer history or massive hepatomegaly 10

Supportive Care Management

Central Nervous System Management

Patients with acute liver failure should be monitored for mental status frequently and transferred to ICU if level of consciousness declines 11
Positioning the patient with head elevated at 30 degrees and minimizing stimulation is recommended for central nervous system management 11
For grades III-IV encephalopathy, intubation is recommended for airway protection 11
Control of seizures with phenytoin is advised, while avoiding benzodiazepines when possible 11
Lactulose administration may be considered to reduce ammonia levels, though evidence for improved outcomes is limited 11

Coagulation Management

Administration of vitamin K is recommended for patients with acute liver failure 11
Fresh frozen plasma (FFP) should be reserved for invasive procedures or active bleeding 11
Platelets should be given for counts <10,000/mm³ or before invasive procedures 11
Recombinant activated factor VII may be considered for invasive procedures 11

Renal Support

Nephrotoxic agents should be avoided in patients with acute liver failure 11
If dialysis is needed, continuous modes rather than intermittent hemodialysis are preferred 11

Infection Prevention and Management

Prophylaxis for stress ulceration with H2 blockers or proton pump inhibitors is recommended 11
Avoidance of nephrotoxic agents is also crucial for preventing renal complications 11

Initial Treatment for Acute Liver Failure

Diagnosis and Initial Assessment

The American Association for the Study of Liver Diseases defines acute liver failure (ALF) by the presence of coagulopathy and any degree of altered mental status in a patient without pre-existing liver disease, with illness duration ≤26 weeks 12
Immediate laboratory evaluation for ALF should include prothrombin time/INR, comprehensive metabolic panel, arterial blood gases, lactate, complete blood count, acetaminophen level, toxicology screen, viral hepatitis serologies, and other tests based on clinical suspicion 12

Etiology-Specific Initial Treatments

For acetaminophen-induced ALF, N-acetylcysteine (NAC) should be administered immediately (140 mg/kg orally or via nasogastric tube followed by 70 mg/kg every 4 hours for 17 doses) even if >48 hours since ingestion 12

Diagnostic Criteria and Initial Evaluation for Acute Liver Failure

Initial Laboratory Evaluation

A complete blood count and ferritin levels should be obtained at baseline, and renal function tests (creatinine, BUN, eGFR) should be performed to assess the patient's condition 13
A comprehensive metabolic panel including liver function tests (AST, ALT, alkaline phosphatase, total and direct bilirubin) should be conducted to evaluate liver function 14

Imaging and Additional Testing

Transjugular liver biopsy may be helpful when etiology remains unclear after routine evaluation, and can provide valuable information for diagnosis and treatment 14
Neurological evaluation is often useful between attacks for assessment of positive neurological findings, and can help identify potential complications 13

Common Pitfalls and Caveats

Malignant infiltration of the liver can mimic Acute Liver Failure and should be considered in patients with previous cancer history or massive hepatomegaly, as noted by the American Association for the Study of Liver Diseases 14

Initial Management of Acute Liver Failure

Definition and Diagnosis

The American Association for the Study of Liver Diseases defines acute liver failure (ALF) by coagulation abnormality (typically INR ≥1.5) and any degree of mental alteration (encephalopathy) in patients without preexisting cirrhosis with illness duration ≤26 weeks 15
Immediate measurement of prothrombin time and careful evaluation for subtle alterations in mentation are essential for diagnosis in patients with suspected ALF 15
Hospital admission is mandatory when prothrombin time is prolonged by 4-6 seconds or more (INR ≥1.5) and there is any evidence of altered sensorium in patients with ALF 15

Initial Assessment

A complete history should focus on possible exposures to viral infections, drugs, or toxins in patients with ALF 15
Physical examination must include careful assessment of mental status and search for stigmata of chronic liver disease in patients with ALF 15
Initial laboratory evaluation should include prothrombin time/INR 15, complete metabolic panel (sodium, potassium, chloride, bicarbonate, calcium, magnesium, phosphate, glucose) 15, and liver function tests (AST, ALT, alkaline phosphatase, GGT, total bilirubin, albumin) 15

Etiology-Specific Management

Autoimmune Hepatitis

The American Association for the Study of Liver Diseases recommends considering liver biopsy to establish diagnosis in patients with autoimmune hepatitis-related ALF 16
Treatment with corticosteroids (prednisone, 40-60 mg/day) is recommended for patients with autoimmune hepatitis-related ALF 16
Patients with autoimmune hepatitis-related ALF should be placed on the transplant list even while administering corticosteroids 16

Acute Fatty Liver of Pregnancy/HELLP Syndrome

The American College of Obstetricians and Gynecologists recommends consulting obstetrical services and performing expeditious delivery in patients with acute fatty liver of pregnancy/HELLP syndrome 16

Role of Plasmapheresis in Acute Liver Failure

Indications and Benefits

Plasmapheresis is indicated as a bridging therapy until liver transplantation can be performed in patients with acute liver failure, as recommended by the American Association for the Study of Liver Diseases 17, 18
Plasmapheresis may protect the kidneys from copper-mediated tubular damage in patients with Wilson's disease awaiting transplantation, according to the American Association for the Study of Liver Diseases 17, 19, 20
The procedure can stabilize patients with acute liver failure and delay, though not eliminate, the need for transplantation, as stated by the American Association for the Study of Liver Diseases 17, 19, 20

Alternative Liver Support Systems

Albumin dialysis has also been shown to stabilize patients with acute liver failure due to Wilson's disease, as reported by the American Association for the Study of Liver Diseases 17, 19, 20
The Molecular Adsorbents Recirculating System (MARS) ultrafiltration device may be efficacious as an alternative to plasmapheresis, according to the American Association for the Study of Liver Diseases 17, 21

Acute Liver Failure Management

Patient Care and Monitoring

The European Association for the Study of the Liver recommends that all patients with acute liver failure require ICU or intermediate care unit admission for continuous monitoring of liver, kidney, brain, lung, coagulation, and circulation 22, 23
The American Society of Anesthesiologists suggests avoiding benzodiazepines as they worsen encephalopathy, and instead use propofol for sedation due to favorable pharmacokinetics, and avoid dexmedetomidine due to exclusive hepatic metabolism 23
The European Society of Anaesthesiology recommends controlling seizures with phenytoin, adding diazepam only as needed, and consider lactulose to reduce ammonia levels, though evidence for improved outcomes is limited 23
The International Liver Transplantation Society indicates that urgent liver transplantation is indicated when prognostic indicators suggest high likelihood of death, and list patients early in the course of ALF, particularly those suitable for transplant 22

Renal and Respiratory Support

The European Renal Association recommends using continuous renal replacement therapy rather than intermittent hemodialysis if dialysis is needed, and for hepatorenal syndrome, treat with terlipressin and albumin (or norepinephrine if terlipressin unavailable) 22
The American Thoracic Society suggests providing oxygen therapy and mechanical ventilation if respiratory failure develops, and use protective ventilation settings per critical care guidelines 22, 23
The Society of Critical Care Medicine recommends avoiding high PEEP (>10 cmH₂O) due to risk of hepatic congestion 23

Infection Prevention and Management

The Infectious Diseases Society of America recommends screening aggressively for infections and treat early, as bacterial infections are common precipitants 22

Prognostic Indicators

The American Association for the Study of Liver Diseases indicates that King's College criteria remain the best prognostic tool, though sensitivity is limited (50-60%) 23
The European Association for the Study of the Liver recommends that for ACLF-3 with organ failures ≥4 or CLIF-C ACLFs >64 at days 3-7, discontinue intensive support if transplant is contraindicated or unavailable due to futility 22

Management of Acute Liver Failure

Immediate Actions and ICU Admission

The American Association for the Study of Liver Diseases recommends that all patients with acute liver failure be admitted to an intensive care unit with frequent monitoring, and early contact with a liver transplant center should be initiated immediately 24
Contact a transplant center early in the evaluation process, as the "transplantation window" is often narrow 24
Alternative oral dosing of N-acetylcysteine: 140 mg/kg by mouth or nasogastric tube, followed by 70 mg/kg every 4 hours for 17 doses 24
Continue N-acetylcysteine even if >48 hours since acetaminophen ingestion 24

Etiology Determination and Specific Antidotes

Obtain immediately: acetaminophen level, prothrombin time/INR, comprehensive metabolic panel, arterial blood gases, lactate, complete blood count, toxicology screen, viral hepatitis serologies, ceruloplasmin, 24-hour urine copper, and slit-lamp examination if age <40 years 24
Autoimmune markers (ANA, ASMA, IgG) should be obtained if suspected 25
Activated charcoal (1 g/kg orally) if presentation within 4 hours of acetaminophen ingestion, given just prior to NAC 24

Etiology-Specific Treatments

Liver biopsy to confirm diagnosis of autoimmune hepatitis 25
Prednisone 40-60 mg/day for autoimmune hepatitis 25
List for transplantation even while administering corticosteroids for autoimmune hepatitis 25
Expeditious delivery with obstetrical consultation for acute fatty liver of pregnancy/HELLP syndrome 25
Recovery typically rapid after delivery with supportive care only for acute fatty liver of pregnancy/HELLP syndrome 25
Cardiovascular support is the treatment of choice for ischemic hepatitis ("shock liver") 25
Transplantation seldom indicated for ischemic hepatitis ("shock liver") 25
Transplantation indicated if significant liver failure present for Budd-Chiari syndrome 25
Exclude underlying malignancy before transplantation for Budd-Chiari syndrome 25

Hemodynamic Management

Maintain mean arterial pressure ≥50-60 mmHg through aggressive fluid resuscitation first 25
Consider vasopressors: epinephrine, norepinephrine, or dopamine (NOT vasopressin) if fluid replacement fails 25

Management of Acute Liver Failure

Patient Assessment and Monitoring

The American Association for the Study of Liver Diseases recommends continuous monitoring of liver, kidney, brain, lung, coagulation, and circulation in all ALF patients, with a focus on maintaining mean arterial pressure ≥50-60 mm Hg through aggressive fluid resuscitation and vasopressors if needed 26
The American Association for the Study of Liver Diseases suggests that fluid resuscitation with colloid (albumin) is preferred over crystalloid (saline), and all solutions should contain dextrose to maintain euglycemia 26

Etiology-Specific Management

The American Association for the Study of Liver Diseases recommends obtaining liver biopsy via transjugular approach to confirm diagnosis of autoimmune hepatitis 27
The American Association for the Study of Liver Diseases suggests that systemic corticosteroids should not be used for general ALF treatment, except in cases of autoimmune hepatitis 27

Hemodynamic Management

The American Association for the Study of Liver Diseases recommends maintaining mean arterial pressure ≥50-60 mm Hg through aggressive fluid resuscitation and vasopressors if needed, with dopamine associated with increased systemic oxygen delivery in ALF 26
The American Association for the Study of Liver Diseases suggests that if fluid replacement fails, epinephrine, norepinephrine, or dopamine should be used, but not vasopressin 26

Neurological Management

The American Society of Anesthesiologists recommends using propofol for sedation due to favorable pharmacokinetics, and avoiding benzodiazepines as they worsen encephalopathy 28
The American Society of Anesthesiologists suggests that serum sodium should be maintained at 140-145 mmol/L, and infusion of hypertonic saline can significantly decrease intracranial pressure 28

Coagulation Management

The American Society of Anesthesiologists recommends reserving fresh frozen plasma and coagulation factors for active bleeding or invasive procedures only, and prophylactic administration of coagulation factors is not supported 28
The American Society of Anesthesiologists suggests that most ALF patients have rebalanced hemostasis between pro- and anticoagulant factors, and bleeding complications occur in only 10% of patients 28

Renal Management

The American Association for the Study of Liver Diseases recommends using continuous renal replacement therapy rather than intermittent hemodialysis if dialysis is needed 26
The American Society of Anesthesiologists suggests that regional citrate anticoagulation should be monitored due to potential metabolic effects in ALF 28

Metabolic Management

The American Association for the Study of Liver Diseases recommends monitoring blood glucose at least every 2 hours and managing hypoglycemia with continuous glucose infusions 26
The American Society of Anesthesiologists suggests that serum sodium should be maintained at 140-145 mmol/L 28

Nutritional Support

The American Association for the Study of Liver Diseases recommends initiating enteral feedings early with moderate protein intake (approximately 60 grams per day), and severe protein restrictions should be avoided 26
The American Association for the Study of Liver Diseases suggests that branched-chain amino acids have not been shown superior to other enteral preparations 26

Liver Transplantation

The American Association for the Study of Liver Diseases recommends urgent hepatic transplantation when prognostic indicators suggest high likelihood of death, with post-transplant survival rates reaching 80-90% even in patients with multiple organ failures 26
The American Association for the Study of Liver Diseases suggests that King's College criteria remain the best prognostic tool, though sensitivity is limited (50-60%) 26

Plasmapheresis in Acute Liver Failure

The American Association for the Study of Liver Diseases recommends plasmapheresis as part of the treatment strategy for Wilson disease-related acute liver failure, where it serves to acutely lower serum copper and limit further hemolysis, in patients awaiting liver transplantation 29
Alternative liver support systems, including albumin dialysis and continuous hemofiltration, are equally acceptable options for copper reduction in Wilson disease, as recommended by the American Association for the Study of Liver Diseases 29

Critical Caveats

Plasmapheresis should be used cautiously in patients with severe HCV liver disease, with careful monitoring of HCV/HBV infection evolution, particularly when combined with immunosuppressants, as warned by guidelines from the Autoimmunity Reviews 30

Comparison to Other Liver Support Systems

The Molecular Adsorbents Recirculating System (MARS) and other sorbent-based systems show only transient improvement in hepatic encephalopathy without clear long-term benefit, according to research published in Hepatology 31

Management of Liver Failure with Emphasis on Prophylaxis and Supportive Care

Gastrointestinal Bleeding Prophylaxis and Hemodynamic Management

Patients with acute liver failure in the ICU should receive prophylaxis with H2 blocking agents or proton pump inhibitors for acid-related gastrointestinal bleeding associated with stress, as recommended by the American Association for the Study of Liver Diseases 32
H2 blockers, such as ranitidine, have proven effectiveness in preventing GI bleeding, and proton pump inhibitors may provide superior protection, according to the American Association for the Study of Liver Diseases 32
Sucralfate may be acceptable as second-line treatment for gastrointestinal bleeding prophylaxis, as suggested by the American Association for the Study of Liver Diseases 32
Fluid resuscitation with colloid, such as albumin, is preferred over crystalloid for maintaining mean arterial pressure ≥50-60 mm Hg, as recommended by the American Association for the Study of Liver Diseases 32
Continuous renal replacement therapy is preferred over intermittent hemodialysis for dialysis support in acute renal failure, according to the American Association for the Study of Liver Diseases 32

Acute Liver Failure Management with Hemodynamic Support

Hemodynamic Management

Consider pulmonary artery catheterization in hemodynamically unstable patients, as recommended by the American Association for the Study of Liver Diseases, to guide fluid and vasopressor management 33

Diagnosis and Initial Management of Acute Liver Failure

Diagnostic Criteria

Acute liver failure is defined by the presence of coagulopathy (INR ≥ 1.5, corresponding to a prothrombin time prolonged ≥4–6 seconds) and any grade of hepatic encephalopathy occurring within 26 weeks of illness onset in a patient without pre‑existing cirrhosis. – American Association for the Study of Liver Diseases (AASLD) 34
Patients with Wilson disease, vertically‑acquired hepatitis B, or autoimmune hepatitis may be classified as having acute liver failure even if cirrhosis is present, provided the disease has been recognized for ≤26 weeks. – AASLD 34

Initial Clinical Assessment

History

Elicit recent viral exposure risk factors (travel, sick contacts, sexual history, injection drug use) to identify possible viral hepatitis. – AASLD 34
Ask about recent pregnancy complications (especially third‑trimester) because pregnancy‑related acute liver failure (e.g., HELLP, acute fatty liver) requires obstetric intervention. – AASLD 35
Document cardiovascular events (hypotension, cardiac arrest, heart failure) that can precipitate ischemic (“shock”) hepatitis. – AASLD 35

Physical Examination

Grade mental status from subtle confusion to coma to quantify encephalopathy severity. – AASLD 34
Assess for jaundice, liver size (palpation/percussion), and right‑upper‑quadrant tenderness; an enlarged liver suggests viral hepatitis, malignant infiltration, cardiac failure, or Budd‑Chiari syndrome. – AASLD 34
Look for stigmata of chronic liver disease (spider angiomas, palmar erythema, gynecomastia); their absence supports the diagnosis of acute rather than chronic failure. – AASLD 34
Presence of ascites and hepatomegaly should raise suspicion for Budd‑Chiari syndrome. – AASLD 35

Laboratory Evaluation

Obtain a coagulation panel with prothrombin time/INR; an INR ≥ 1.5 is the diagnostic threshold. – AASLD 34
Perform blood typing and screen to prepare for possible transfusion. – AASLD 35
Check serum glucose because hypoglycemia is common in acute liver failure. – AASLD 35
Measure serum creatinine and blood urea nitrogen; renal dysfunction worsens prognosis. – Anaesthesia Society 36
Obtain arterial lactate; elevated lactate is a prognostic marker. – Anaesthesia Society 36
Test acetaminophen level even without a clear ingestion history to detect occult toxicity. – Anaesthesia Society 36
Conduct a comprehensive toxicology screen to identify other drug exposures. – AASLD 34
Order viral serologies (anti‑HAV IgM, HBsAg, anti‑HBc IgM, anti‑HEV, anti‑HCV) to identify infectious etiologies. – AASLD 34
Measure ceruloplasmin in patients ≤40 years or when Wilson disease is suspected. – AASLD 34
Evaluate autoimmune markers (ANA, ASMA, immunoglobulins) when autoimmune hepatitis is a consideration. – AASLD 34
Perform a pregnancy test in all women of child‑bearing potential. – AASLD 34
Assess HIV status because it influences transplant eligibility. – AASLD 34
Calculate the uric acid / bilirubin‑to‑alkaline phosphatase ratio when Wilson disease is in the differential. – AASLD 34

Imaging Studies

Perform Doppler ultrasonography to evaluate hepatic vasculature, exclude Budd‑Chiari syndrome, and assess liver size/echogenicity. – AASLD 35
If Budd‑Chiari syndrome is suspected (based on ascites, hepatomegaly, abdominal pain), obtain contrast‑enhanced CT or MR venography for definitive vascular imaging. – AASLD 35
Use transthoracic echocardiography to identify cardiac dysfunction in cases of suspected ischemic (“shock”) hepatitis. – AASLD 35
Consider transjugular liver biopsy when the etiology remains unclear, especially for suspected autoimmune hepatitis, because it is safer in coagulopathic patients. – AASLD 35

Immediate Management

Hospital admission to an intensive‑care unit is mandatory once acute liver failure is diagnosed (INR ≥ 1.5 + encephalopathy). – AASLD 34
Early ICU transfer is recommended because the clinical condition can deteriorate hour‑by‑hour. – AASLD 34; Anaesthesia Society 36
Continuous monitoring of hepatic, renal, neurologic, pulmonary, coagulation, and hemodynamic parameters is essential for early detection of organ failure. – Anaesthesia Society 36
Do not correct INR prophylactically with plasma or clotting factor concentrates unless there is active bleeding or an invasive procedure, because acute liver failure exhibits a “rebalanced” hemostasis. – AASLD 34

Prognostic Assessment

King’s College Criteria – acetaminophen‑induced ALF: Poor prognosis if arterial pH < 7.3 after resuscitation or if all three of the following are present: INR > 6.5, serum creatinine > 300 µmol/L, and grade 3–4 encephalopathy. – Anaesthesia Society 36
King’s College Criteria – non‑acetaminophen ALF: Poor prognosis if INR > 6.5 or if any three of the following are present: age < 10 years or > 40 years, non‑A/non‑B hepatitis, drug‑induced injury, jaundice > 7 days before encephalopathy, INR > 3.5, bilirubin > 300 µmol/L. – AASLD 34
Additional adverse prognostic markers:
- Serum ammonia > 100–150 µmol/L predicts increased risk of intracranial hypertension. – Anaesthesia Society 36
- Factor V activity < 20 % (Clichy‑Villejuif criteria) indicates poor outcome. – Anaesthesia Society 36
- Requirement for vasopressor support is an independent predictor of mortality. – Anaesthesia Society 36
- Grade 3–4 encephalopathy is associated with only ~33 % short‑term survival without transplantation. – Anaesthesia Society 36

Diagnostic Pitfalls

Acute‑on‑chronic liver failure can mimic acute liver failure but usually shows stigmata of underlying cirrhosis; careful assessment is required. – AASLD 34
Acetaminophen toxicity may occur without a clear ingestion history; routine measurement of serum acetaminophen level is essential. – AASLD 34
Wilson disease should be considered in all patients ≤40 years without an obvious cause, even when initial work‑up is nondiagnostic. – AASLD 34
Pregnancy‑related acute liver failure (e.g., HELLP syndrome, acute fatty liver of pregnancy) mandates prompt obstetric delivery rather than immediate transplantation. – AASLD 35

Evidence‑Based Management and Prognostication in Acute Fulminant Hepatic Failure

Transplant Referral and Timing

Early contact with a liver‑transplant center within the first hours after diagnosis of acute liver failure improves patient outcomes (Anaesthesia 2020) 37.
Rapid, multidisciplinary decision‑making is essential because the transplantation window is narrow (Anaesthesia 2020) – expert consensus (Level C) [37][38].

Monitoring and Organ‑Support Strategies

Continuous Multi‑Organ Monitoring

Continuous monitoring of hepatic, renal, neurologic, pulmonary, coagulation, and hemodynamic parameters enables early detection of organ failure in acute liver failure (Anaesthesia 2020) 38.

Renal Replacement Therapy

Continuous renal replacement therapy (CRRT) is preferred over intermittent hemodialysis for renal support in acute liver failure (Anaesthesia 2020) – moderate‑quality evidence 38.

Prognostic Assessment and Outcomes

Survival After Transplantation

Post‑transplant survival in acute liver failure patients with multiple organ failure ranges from 80 % to 90 % (Anaesthesia 2020) – cohort data (moderate quality) 37.
Early liver transplantation provides approximately 78 % one‑year survival compared with < 10 % in patients who are not transplanted (Anaesthesia 2020) – high‑quality comparative data (Level 1) [37][38].

Prognostic Scoring

Using the SOFA score a few days after ICU admission yields more accurate mortality prediction than assessment on admission (Anaesthesia 2020) – observational data (moderate) [37][38].

Artificial Liver Support Systems

Lack of Survival Benefit

The MARS and Prometheus artificial liver support systems do not improve 28‑day or 90‑day survival in randomized controlled trials (Anaesthesia 2020) – Level 1 evidence [37][38].

Potential Clinical Improvements

Post‑hoc analysis of MARS trials shows significant improvement in hepatic encephalopathy and hepatorenal syndrome (Anaesthesia 2020) – secondary outcomes (Level 2) [37][38].
Observational studies suggest artificial liver support may improve short‑term survival (14‑day and 28‑day) and serve as a bridge to transplantation in patients with multiple organ failure (Anaesthesia 2020) – Level 3 evidence [37][38].

Referral Recommendations

Early referral to expert centers is recommended when considering artificial liver support after decompensation (Anaesthesia 2020) – expert recommendation (Level C) [37][38].